Manufacturability and the Winners in Advanced Therapies - Top-Institutions - MDSpire

Manufacturability and the Winners in Advanced Therapies

Are developers still underestimating the engineering sophistication required to scale advanced therapies in the real world? Alan Boyd discusses.

By
Stephanie Vine
January 13, 2026
8 min

The Medicine Maker

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

#1

Stanford University

Stanford, CA
Key Differentiators
- Cell Therapy
- Gene Therapy
- Biomanufacturing
#2

University of Pennsylvania

Philadelphia, PA
Key Differentiators
- Gene Therapy
- Cell Therapy
- Immunotherapy
#3

Massachusetts Institute of Technology (MIT)

Cambridge, MA
Key Differentiators
- Biomanufacturing
- Gene Editing
- Cell Therapy
#4

Cincinnati Children's Hospital Medical Center

Cincinnati, OH
Key Differentiators
- Gene Therapy
- Pediatric Cell Therapy
- Manufacturing
#5

University of California, Los Angeles (UCLA)

Los Angeles, CA
Key Differentiators
- Cell Therapy
- Gene Therapy
- Immunotherapy Manufacturing

Original Source(s)

The Medicine Maker

Manufacturability and the Winners in Advanced Therapies

by Stephanie Vine
January 13, 2026

Related Content

Frontiers In Oncology

Prognostic significance and model evaluation of the modified advanced lung cancer inflammation index in locally advanced resectable gastric cancer patients with neoadjuvant chemotherapy

by Weidong Xie, Yaoyu Song, Zhaojie Yu, Huanhao Zhang, Shaoliang Han
June 4, 2026

Frontiers In Immunology

Identification, design, and in vivo proof of concept of a shared APC neoantigen delivered via a self-amplifying RNA containing virus-like nanoparticle for cancer vaccination

Nature Cancer

Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial